Zealand sidelines CV research as IPO target tumbles
This article was originally published in Scrip
Executive Summary
Investor realism has encouraged Zealand Pharma to reduce the amount of money it is likely to raise through an IPO on the Copenhagen exchange and to decrease its work on its unpartnered early cardiovascular programme in a refocused business strategy. Following its roadshow, the Danish company decided to focus its operations on diabetes and gastrointestinal R&D and reduce its work in cardiovascular disease, CEO Dr David Solomon told Scrip.